HIV PrEP Fundamentals
This Discussion Panel's main goal is to better understand how to use the three FDA-approved medications for HIV PrEP and how to monitor people who are receiving HIV PrEP. Each panelist first discusses what they consider when they are choosing which oral HIV PrEP medications to prescribe to a patient and then they delve into how to ask questions to help create a safe space. They then review injectable cabotegravir including the two key studies, and how it may be more appropriate than oral HIV PrEP for certain populations such as women, and the two options to start a patient on cabotegravir. Prescribers also need to be aware of how to plan for gaps in injections. The conversation then shifts to how implementing injectable cabotegravir in a clinic is a new structural paradigm which needs to be well thought out and could even incorporate peer workers giving injections. When prescribing HIV PrEP to adolescents and young adults, providers need to understand the youth's context, the importance of the check-ins, and state laws around consent. Panelists share what they think the time-to-protection is for oral HIV PrEP medications before sharing words of wisdom for clinicians who are new to HIV PrEP.